HPV drives major public health impacts, including cervical cancer and other HPV-related outcomes for both women and men. This page explains how high-risk HPV infection is detected in cervical screening, from FDA-approved tests that identify high-risk HPV DNA to genotype-specific platforms. It also reviews evidence on how HPV testing can change cancer risk, and summarizes vaccine performance plus real-world results and access programs such as the U.S. Vaccines for Children initiative.
Key Takeaways
- The IARC fact sheet notes that cervical cancer incidence and mortality have substantial economic and health system impacts driven by HPV (measurement: epidemiologic burden leading to costs).
- The global HPV diagnostics market size was $1.6 billion in 2023 (measurement: market size).
- The global HPV vaccines market size was $6.1 billion in 2023 (measurement: market size).
- In 2020, HPV resulted in an estimated 34,000 cases of HPV-associated cancers in the United States.
- WHO estimates that 570,000 women die each year from cervical cancer worldwide.
- 5.8% of women aged 30–64 years had high-risk HPV infection detected in cervical screening in the United States (NHANES, 2015–2016).
- In the pooled analysis of randomized trials reported by Kjaer et al., the number of cervical cancer cases was reduced by 60% with HPV testing compared with cytology (relative effect reported as a reduction).
- Hybrid capture 2 (HC2) is FDA-approved for detecting high-risk HPV DNA as part of cervical screening (measurement: high-risk HPV DNA signal).
- In the phase III FUTURE II trial, HPV 16/18 vaccine (without prior infection) had an efficacy of 98% against HPV 16/18-related cervical intraepithelial neoplasia grade 2 or worse (CIN2+), through the study endpoint (2017 follow-up published as long-term results).
- In the phase III trial of HPV vaccination in women, the vaccine prevented persistent infection with vaccine HPV types, with efficacy reported as 99% against persistent infection (measurement: efficacy against 6- or 12-month persistent infection).
- A 2022 systematic review reported vaccine effectiveness against HPV 16/18-related lesions of about 80% (measurement: effectiveness against CIN2+ and related endpoints in real-world settings).
- HPV vaccine effectiveness against vaccine-type HPV infections can reach about 90% or more in real-world studies (measurement: reduction in infection incidence).
- A reduction of HPV 16/18 prevalence among vaccinated cohorts of young women has been observed in surveillance studies, with declines of roughly 50% reported in post-introduction analyses (measurement: percent prevalence reduction).
- Genital warts incidence decreased by 40% overall among US males aged 15–24 years between 2010 and 2018 (measurement: percent change).
HPV prevention investments drive big market growth and real world drops in cervical cancer and genital warts.
Related reading
01 · Category
Markets And Economics5 stats
01
The IARC fact sheet notes that cervical cancer incidence and mortality have substantial economic and health system impacts driven by HPV (measurement: epidemiologic burden leading to costs).
02
The global HPV diagnostics market size was $1.6 billion in 2023 (measurement: market size).
03
The global HPV vaccines market size was $6.1 billion in 2023 (measurement: market size).
04
The U.S. federal Vaccines for Children (VFC) program provides HPV vaccine doses at no cost to eligible children (measurement: program policy).
05
HPV vaccines are included in national immunization programs in more than 100 countries (measurement: count of countries).
Interpretation
Markets And Economics Interpretation
In 2023, the HPV diagnostics market reached $1.6 billion and the HPV vaccines market grew to $6.1 billion, underscoring how the economic and health system burden of HPV is significant enough to be supported through broad public and national immunization programs in over 100 countries.
02 · Category
Epidemiology Burden2 stats
01
In 2020, HPV resulted in an estimated 34,000 cases of HPV-associated cancers in the United States.
02
WHO estimates that 570,000 women die each year from cervical cancer worldwide.
Interpretation
Epidemiology Burden Interpretation
For the Epidemiology Burden perspective, HPV is responsible for an estimated 34,000 HPV-associated cancer cases in the United States in 2020 while WHO reports 570,000 women die each year worldwide from cervical cancer, underscoring the large and ongoing global disease impact.
03 · Category
Detection And Testing7 stats
01
5.8% of women aged 30–64 years had high-risk HPV infection detected in cervical screening in the United States (NHANES, 2015–2016).
02
In the pooled analysis of randomized trials reported by Kjaer et al., the number of cervical cancer cases was reduced by 60% with HPV testing compared with cytology (relative effect reported as a reduction).
03
Hybrid capture 2 (HC2) is FDA-approved for detecting high-risk HPV DNA as part of cervical screening (measurement: high-risk HPV DNA signal).
04
The Cobas 4800 HPV test reports results for high-risk HPV genotypes, including HPV 16 and HPV 18, as well as other high-risk types (measurement: genotype-specific HPV DNA detection).
05
The OncoE6 2.0/HPV test is a commercially used assay that detects E6/E7 mRNA from high-risk HPV (measurement: E6/E7 mRNA expression).
06
In the PATRICIA trial, HPV testing in low-resource settings achieved a sensitivity of 88% for detecting CIN2+ (measurement: sensitivity).
07
In a systematic review, clinician-collected HPV testing showed pooled sensitivity of about 89% for CIN2+ detection (measurement: sensitivity).
Interpretation
Detection And Testing Interpretation
Detection and testing methods for high risk HPV are strongly supported by evidence showing that high risk HPV is present in 5.8% of screened women in the US and that HPV testing can cut cervical cancer cases by 60% while achieving 88% sensitivity for CIN2+ in low resource settings.
04 · Category
Immunization Uptake3 stats
01
In the phase III FUTURE II trial, HPV 16/18 vaccine (without prior infection) had an efficacy of 98% against HPV 16/18-related cervical intraepithelial neoplasia grade 2 or worse (CIN2+), through the study endpoint (2017 follow-up published as long-term results).
02
In the phase III trial of HPV vaccination in women, the vaccine prevented persistent infection with vaccine HPV types, with efficacy reported as 99% against persistent infection (measurement: efficacy against 6- or 12-month persistent infection).
03
A 2022 systematic review reported vaccine effectiveness against HPV 16/18-related lesions of about 80% (measurement: effectiveness against CIN2+ and related endpoints in real-world settings).
Interpretation
Immunization Uptake Interpretation
Under the immunization uptake lens, the data show very strong real world potential for vaccines, with phase III trials reporting 98% efficacy against HPV 16/18 cervical disease and high prevention of persistent vaccine type infections, while a 2022 systematic review still finds about 80% effectiveness against HPV 16/18 related lesions.
05 · Category
Trends In Real World11 stats
01
HPV vaccine effectiveness against vaccine-type HPV infections can reach about 90% or more in real-world studies (measurement: reduction in infection incidence).
02
A reduction of HPV 16/18 prevalence among vaccinated cohorts of young women has been observed in surveillance studies, with declines of roughly 50% reported in post-introduction analyses (measurement: percent prevalence reduction).
03
Genital warts incidence decreased by 40% overall among US males aged 15–24 years between 2010 and 2018 (measurement: percent change).
04
In Australia, cervical intraepithelial neoplasia (CIN) related to HPV 16/18 showed declines of 50% or more in vaccinated populations after vaccine rollout (measurement: percent reduction).
05
Of HPV infections, about 90% are asymptomatic (measurement: percent asymptomatic).
06
14.7% of US males aged 15–24 had genital warts in 2010 (incidence rate, US males aged 15–24 baseline year).
07
13.0% of US males aged 15–24 had genital warts in 2012 (incidence rate, US males aged 15–24).
08
11.6% of US males aged 15–24 had genital warts in 2014 (incidence rate, US males aged 15–24).
09
10.4% of US males aged 15–24 had genital warts in 2016 (incidence rate, US males aged 15–24).
10
9.4% of US males aged 15–24 had genital warts in 2017 (incidence rate, US males aged 15–24).
11
8.9% of US males aged 15–24 had genital warts in 2018 (incidence rate, end of surveillance period).
Interpretation
Trends In Real World Interpretation
Real world surveillance shows that HPV vaccination is producing measurable population-level impact, including around 90% real-world effectiveness against vaccine type infections and major declines such as about a 40% drop in genital warts among US males aged 15 to 24 from 2010 to 2018.
report visual · Projection
Genital warts incidence declined in US males (15–24) after HPV vaccine rollout
Real-world surveillance shows genital warts incidence in US males aged 15–24 fell steadily over time: the highest level is in 2010, dropping to the lowest by 2018—indicating a sust
14.7 percent
Start
-6.08%
CAGR · 8y
8.9 percent
Projected
20102018
source-verifiedcdc.gov2018
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Leah Kessler. (2026, February 13). Hpv Statistics. Gitnux. https://gitnux.org/hpv-statistics
MLA
Leah Kessler. "Hpv Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/hpv-statistics.
Chicago
Leah Kessler. 2026. "Hpv Statistics." Gitnux. https://gitnux.org/hpv-statistics.
Sources & references
23 datasets cited across this report · attribution is report-level
+12 additional datasets cited (not shown individually)